This great new review at IJMS asks the question: "Hey! With all this better proteomics stuff, can you help us with leukemia yet?"
I dig this as a summary of both the advances in LCMS technology that could feasibly be used within the confines and limitations of a medical environment (double dog dare you to try pitching offline fractionation to a hospital administrator) as well as a summary of the really promising work that has been done in one specific disease.
Table 2 is beautiful and says a ton about the potential of proteomics and our traditional limitations. It says to me: "Here are great studies! Can you imagine what we could do with larger cohorts...?" We'll get there!